AQP4 and neuromyelitis optica: Compounds for treating autoimmune inflammatory diseases such as neuromyelitis optica (NMO) boosted the successful development of monoclonal antibodies as blockers of IgG-AQP4 for the prevention and treatment of NMO lesions [97].